
TAMARA MAES

CV

SCIENTIFIC LEADER AT:

50 YEARS OF HISTONE ACETYLTATION

BARCELONA CONFERENCES ON
EPIGENETICS AND CANCER

October, 1st and 2nd, 2014, Barcelona



Tamara Maes, Chief Scientific Officer at [Oryzon Genomics](http://www.oryzon.com), Barcelona, Spain

Tamara Maes, Ph.D., is co-Founder, Vice President and Chief Scientific Officer of Oryzon Genomics (2000). Dr. Maes holds a B.A. in Chemistry and a Ph.D. in Biotechnology from the University of Ghent, Belgium. The Mission of Oryzon is the identification of new biomarkers and their exploitation in diagnostics assays or as drug targets. Under Dr. Maes' leadership, the company completed the cycle of marker discovery, clinical validation and commercial implementation of a CE marked IVDIA assay that improves minimally invasive detection of endometrial cancer, in a collaborative project including The Vall d'Hebron hospital and Reig-Jofre. In 2008, the company launched its first proprietary drug discovery program directed against LSD1, a novel target identified previously in its biomarker programs in neurodegenerative disease in a collaboration with Dr. Isidre Ferrer (IDIBELL). By 2012, Oryzon developed a leader position in the development of inhibitors directed against this epigenetic drug target, with potential uses in oncology and neurodegenerative diseases. The first of these drugs, licensed to Roche, is currently in Phase I studies for the treatment of Acute Leukemia and the second is in regulatory preclinical development for the treatment of neurodegenerative disease.

B-DEBATE IS AN INITIATIVE OF:

www.bdebate.org